Subarachnoid hemorrhage: Difference between revisions

No edit summary
Line 3: Line 3:
=== Pearls  ===
=== Pearls  ===


#Obtain GCS before intubation  
*Obtain GCS before intubation  
#If intubate prevent HTN (rebleeding)  
*If intubate prevent HTN (rebleeding)  
##Pretreatment  
**Pretreatment  
###Lidocaine 1-1.5mg/kg (100mg) (blunts incr in BP)  
***Lidocaine 1-1.5mg/kg (100mg) (blunts incr in BP)  
###Fentanyl 200mcg (sympatholytic)
***Fentanyl 200mcg (sympatholytic)
##Sedation  
**Sedation  
###If pt has high BP - use propofol  
***If pt has high BP - use propofol  
###If pt has adequate BP - use etomidate
***If pt has adequate BP - use etomidate
##Treat pain  
**Treat pain  
###Prevents incr catacholamines / incr BP
***Prevents incr catacholamines / incr BP


=== Epidemiology  ===
=== Epidemiology  ===
Line 23: Line 23:
=== Risk Factors  ===
=== Risk Factors  ===


#Genetics (polycystic kidney disease, Ehler-Danlos, family hx)  
*Genetics (polycystic kidney disease, Ehler-Danlos, family hx)  
#Hypertension  
*Hypertension  
#Atherosclerosis  
*Atherosclerosis  
#Cigarette smoking  
*Cigarette smoking  
#Alcohol  
*Alcohol  
#Age >50  
*Age >50  
#Cocaine use  
*Cocaine use  
#Estrogen deficiency
*Estrogen deficiency


=== Etiology of Spontaneous SAH  ===
=== Etiology of Spontaneous SAH  ===


#Ruptured aneurysm (85%)  
*Ruptured aneurysm (85%)  
#Nonaneurysmal (15%)  
*Nonaneurysmal (15%)  
##Perimesencephalic hemorrhage (10%) - lower risk of complications
**Perimesencephalic hemorrhage (10%) - lower risk of complications
##Other: tumor, coagulopathy, dissection, vasculitis, SCD, venous sinus thrombosis
**Other: tumor, coagulopathy, dissection, vasculitis, SCD, venous sinus thrombosis


== Clinical Features ==
== Clinical Features ==


#Sudden, severe headache that reaches maximal intensity within minutes (97% of cases)  
*Sudden, severe headache that reaches maximal intensity within minutes (97% of cases)  
##Sudden onset is more important finding than worst HA
**Sudden onset is more important finding than worst HA
#May be a/w syncope, seizure, nausea/vomiting, meningismus  
*May be a/w syncope, seizure, nausea/vomiting, meningismus  
##Meningismus may not develop until hrs after bleed (blood breakdown -> aseptic meningitis)
**Meningismus may not develop until hrs after bleed (blood breakdown -> aseptic meningitis)
#Retinal hemorrhage  
*Retinal hemorrhage  
##May be the only clue in comatose patients
**May be the only clue in comatose patients
#Sentinel bleed/HA 6-20d before SAH (30-50% of pts)
*Sentinel bleed/HA 6-20d before SAH (30-50% of pts)


== Differential Diagnosis ==
== Differential Diagnosis ==
Line 53: Line 53:


===Other===  
===Other===  
#Drug toxicity  
*Drug toxicity  
#Ischemic [[Stroke (Main)|Stroke]]  
*Ischemic [[Stroke (Main)|Stroke]]  
#[[Meningitis]]  
*[[Meningitis]]  
#[[Encephalitis]]
*[[Encephalitis]]
#Intracranial tumor  
*Intracranial tumor  
#Intracranial hypotension  
*Intracranial hypotension  
#Metabolic derangements  
*Metabolic derangements  
#[[Cerebral venous thrombosis]]  
*[[Cerebral venous thrombosis]]  
#Primary headache syndromes (benign thunderclap headache, [[Migraine]], [[Cluster Headache]])
*Primary headache syndromes (benign thunderclap headache, [[Migraine]], [[Cluster Headache]])


== Diagnosis  ==
== Diagnosis  ==
Line 79: Line 79:
===Non-Contrast Head CT ===
===Non-Contrast Head CT ===
====Sensitivity====
====Sensitivity====
#Within 6hr of onset of symptoms: Near 100% Sn<ref>Perry JJ, et al. Sensitivity of computed tomography performed within six hours of onset of headache for diagnosis of subarachnoid haemorrhage: prospective cohort study. BMJ. 2011; 343:d4277.
</ref>  
*Within 6hr of onset of symptoms: Near 100% Sn<ref>Perry JJ, et al. Sensitivity of computed tomography performed within six hours of onset of headache for diagnosis of subarachnoid haemorrhage: prospective cohort study. BMJ. 2011; 343:d4277.
</ref>  
#Within 12hr of onset of symptoms: 98% Sn  
*Within 12hr of onset of symptoms: 98% Sn  
#Within 24hr of onset of symptoms: 93% Sn<ref>van Gijn J and van Dongen KJ. The time course of aneurysmal haemorrhage on computed tomograms. Neuroradiology. 1982; 23:153–156.</ref>
*Within 24hr of onset of symptoms: 93% Sn<ref>van Gijn J and van Dongen KJ. The time course of aneurysmal haemorrhage on computed tomograms. Neuroradiology. 1982; 23:153–156.</ref>
#Within 5d of onset of symptoms: <60% Sn  
*Within 5d of onset of symptoms: <60% Sn  
#Not as sensitive/specific for minor bleeds
*Not as sensitive/specific for minor bleeds


====Findings====
====Findings====
#SAH due to aneurysm - look in cisterns (esp. suprasellar cistern)  
*SAH due to aneurysm - look in cisterns (esp. suprasellar cistern)  
#SAH due to trauma - look at convexities of frontal and temporal cortices
*SAH due to trauma - look at convexities of frontal and temporal cortices


===Lumbar Puncture===  
===Lumbar Puncture===  
====Findings====
====Findings====
#Elevated RBC count that doesn't decrease from tube one to four  
*Elevated RBC count that doesn't decrease from tube one to four  
##Note: decreasing RBCs in later tubes can occur in SAH; only reliable if RBC count in final tube is nl
**Note: decreasing RBCs in later tubes can occur in SAH; only reliable if RBC count in final tube is nl
#Opening pressure &gt;20 (60% of pts)  
*Opening pressure &gt;20 (60% of pts)  
##Can help differentiate from a traumatic tap (opening pressure expected to be normal)  
**Can help differentiate from a traumatic tap (opening pressure expected to be normal)  
##Elevated opening pressure also seen in cerebral venous thrombosis, IIH
**Elevated opening pressure also seen in cerebral venous thrombosis, IIH
#Xanthrochromia  
*Xanthrochromia  
##May help differentiate between SAH and a traumatic tap  
**May help differentiate between SAH and a traumatic tap  
##Takes at least 2hr after bleed to develop (beware of false negative if measure early)  
**Takes at least 2hr after bleed to develop (beware of false negative if measure early)  
##Sn (93%) / Sp (95%) highest after 12hr
**Sn (93%) / Sp (95%) highest after 12hr
#If unable to obtain CSF consider CTA
*If unable to obtain CSF consider CTA
##CTA also highly sensitive for predicting delayed cerebral ischemia
**CTA also highly sensitive for predicting delayed cerebral ischemia


==Workup==
==Workup==
Line 113: Line 113:




#Avoid hypotension  
*Avoid hypotension  
##Maintain MAP &gt;80  
**Maintain MAP &gt;80  
##Give IVF  
**Give IVF  
##Give pressors if IVF ineffective
**Give pressors if IVF ineffective
#Discontinue/reverse all anticoagulation  
*Discontinue/reverse all anticoagulation  
##Coumadin - (Prothrombin complex conc or FFP) + vit K  
**Coumadin - (Prothrombin complex conc or FFP) + vit K  
##Aspirin - DDAVP  
**Aspirin - DDAVP  
##Plavix - Platelets
**Plavix - Platelets
#Nimodipine  
*Nimodipine  
##Prevents vasospasm (a/w improved neuro outcomes and decreased cerebral infarction)  
**Prevents vasospasm (a/w improved neuro outcomes and decreased cerebral infarction)  
##Give 60mg q4hr PO or NGT only (never IV) within 96hr of symptom onset. NNT 13 to prevent one poor outcome
**Give 60mg q4hr PO or NGT only (never IV) within 96hr of symptom onset. NNT 13 to prevent one poor outcome
##Keep an eye on BP for fluctuations
**Keep an eye on BP for fluctuations
#Magneisum
*Magneisum
##Controversial; prevents vasospasm acting as NMDA antagonist and a calcium channel blocker; maintain b/w 2-2.5 mmol/L
**Controversial; prevents vasospasm acting as NMDA antagonist and a calcium channel blocker; maintain b/w 2-2.5 mmol/L
#Seizure prophylaxis  
*Seizure prophylaxis  
##Controversial; 3 day course may be preferable  
**Controversial; 3 day course may be preferable  
##Phenytoin, levetiracetam, carbamazepine and phenobarb. Phenytoin can be a/w worse neurologic & cognitive outcome
**Phenytoin, levetiracetam, carbamazepine and phenobarb. Phenytoin can be a/w worse neurologic & cognitive outcome
#Glucocorticoid therapy  
*Glucocorticoid therapy  
##Controversial; evidence suggests is neither beneficial nor harmful
**Controversial; evidence suggests is neither beneficial nor harmful
#Glycemic control  
*Glycemic control  
##Controversial; consider sliding scale if long pt stay in ED while awaiting ICU bed
**Controversial; consider sliding scale if long pt stay in ED while awaiting ICU bed
#Keep head of bed elevated  
*Keep head of bed elevated  
#Aneurysm Tx
*Aneurysm Tx
##Surgical clipping and endovascular coiling are definitive tx
**Surgical clipping and endovascular coiling are definitive tx
##Antifibrinolytic - Controversial; if delayed aneurysmal tx, consider short term therapy (<72 hrs) with TXA or aminocaproic acid
**Antifibrinolytic - Controversial; if delayed aneurysmal tx, consider short term therapy (<72 hrs) with TXA or aminocaproic acid


== Complications  ==
== Complications  ==


#Rebleeding  
*Rebleeding  
##Risk is highest within first 24 hours (2.5-4%), particularly within first 6 hours  
**Risk is highest within first 24 hours (2.5-4%), particularly within first 6 hours  
##Usually diagnosed by CT after acute deterioration in neuro status  
**Usually diagnosed by CT after acute deterioration in neuro status  
##Only aneurysm treatment is effective in preventing rebleeding
**Only aneurysm treatment is effective in preventing rebleeding
#Vasospasm  
*Vasospasm  
##Leading cause of death and disability after rupture  
**Leading cause of death and disability after rupture  
##Typically begins no earlier than day three after hemorrhage  
**Typically begins no earlier than day three after hemorrhage  
##Characterized by decline in neuro status  
**Characterized by decline in neuro status  
##Aggressive treatment can only be started after aneurysm has been treated
**Aggressive treatment can only be started after aneurysm has been treated
###Tx for symptomatic vasospasm: Triple-H therapy (hemodilution + induced hypertension (pressors) + hypervolemia), ballon angioplasty, or intra-arterial vasodilators.
***Tx for symptomatic vasospasm: Triple-H therapy (hemodilution + induced hypertension (pressors) + hypervolemia), ballon angioplasty, or intra-arterial vasodilators.
####Studies have not provided strong evidence of benefit Triple-H therapy
****Studies have not provided strong evidence of benefit Triple-H therapy
#Cardiac abnormalities (?2/2 release of catecholamines due to hypoperfusion of hypothalamus)  
*Cardiac abnormalities (?2/2 release of catecholamines due to hypoperfusion of hypothalamus)  
##Ischemia  
**Ischemia  
###Elevated troponin (20-40% of cases)  
***Elevated troponin (20-40% of cases)  
###ST segment depression
***ST segment depression
##Rhythm disturbances  
**Rhythm disturbances  
###Torsades, A-fib/flutter
***Torsades, A-fib/flutter
##QT prolongation  
**QT prolongation  
##Deep, symmetric TWI  
**Deep, symmetric TWI  
##Prominent U waves
**Prominent U waves
#Hydrocephalus  
*Hydrocephalus  
##Consider ventricular drain placement for deteriorating LOC + no improvement w/in 24hr
**Consider ventricular drain placement for deteriorating LOC + no improvement w/in 24hr
#Hyponatremia  
*Hyponatremia  
##Usually due to SIADH  
**Usually due to SIADH  
###Treat via isotonic, or if necessary, hypertonic saline (do not treat via H2O restriction)
***Treat via isotonic, or if necessary, hypertonic saline (do not treat via H2O restriction)
##Rarely due to cerebral salt-wasting
**Rarely due to cerebral salt-wasting
###Volume depleted, so treat with isotonic saline
***Volume depleted, so treat with isotonic saline


== Prognosis  ==
== Prognosis  ==

Revision as of 01:37, 12 March 2015

Background

  • Abreviation: SAH

Pearls

  • Obtain GCS before intubation
  • If intubate prevent HTN (rebleeding)
    • Pretreatment
      • Lidocaine 1-1.5mg/kg (100mg) (blunts incr in BP)
      • Fentanyl 200mcg (sympatholytic)
    • Sedation
      • If pt has high BP - use propofol
      • If pt has adequate BP - use etomidate
    • Treat pain
      • Prevents incr catacholamines / incr BP

Epidemiology

  • Of All pts in ED who p/w HA:
    • 1% will have SAH
    • 10% will have SAH if c/o worst HA of life
    • 25% will have SAH if c/o worst HA of life + any neuro deficit

Risk Factors

  • Genetics (polycystic kidney disease, Ehler-Danlos, family hx)
  • Hypertension
  • Atherosclerosis
  • Cigarette smoking
  • Alcohol
  • Age >50
  • Cocaine use
  • Estrogen deficiency

Etiology of Spontaneous SAH

  • Ruptured aneurysm (85%)
  • Nonaneurysmal (15%)
    • Perimesencephalic hemorrhage (10%) - lower risk of complications
    • Other: tumor, coagulopathy, dissection, vasculitis, SCD, venous sinus thrombosis

Clinical Features

  • Sudden, severe headache that reaches maximal intensity within minutes (97% of cases)
    • Sudden onset is more important finding than worst HA
  • May be a/w syncope, seizure, nausea/vomiting, meningismus
    • Meningismus may not develop until hrs after bleed (blood breakdown -> aseptic meningitis)
  • Retinal hemorrhage
    • May be the only clue in comatose patients
  • Sentinel bleed/HA 6-20d before SAH (30-50% of pts)

Differential Diagnosis

Intracranial Hemorrhage Types

Other

Diagnosis

Ottawa SAH Rules[1]

Never has been externally and prospectively validated, authors caution implementation into routine use

  • 100% sensitive to rule out SAH (97.1%-100%)
  • Can exclude SAH if all of the following are true
    • Age < 40
    • No Neck pain or stiffness
    • No Witnessed LOC
    • No onset during exertion
    • No Thunderclap symptomatology (max intensity at honest)
    • No limited neck flexion on physical exam

If concerned for SAH and CT normal strongly consider LP

Non-Contrast Head CT

Sensitivity

  • Within 6hr of onset of symptoms: Near 100% Sn[2]
  • Within 12hr of onset of symptoms: 98% Sn
  • Within 24hr of onset of symptoms: 93% Sn[3]
  • Within 5d of onset of symptoms: <60% Sn
  • Not as sensitive/specific for minor bleeds

Findings

  • SAH due to aneurysm - look in cisterns (esp. suprasellar cistern)
  • SAH due to trauma - look at convexities of frontal and temporal cortices

Lumbar Puncture

Findings

  • Elevated RBC count that doesn't decrease from tube one to four
    • Note: decreasing RBCs in later tubes can occur in SAH; only reliable if RBC count in final tube is nl
  • Opening pressure >20 (60% of pts)
    • Can help differentiate from a traumatic tap (opening pressure expected to be normal)
    • Elevated opening pressure also seen in cerebral venous thrombosis, IIH
  • Xanthrochromia
    • May help differentiate between SAH and a traumatic tap
    • Takes at least 2hr after bleed to develop (beware of false negative if measure early)
    • Sn (93%) / Sp (95%) highest after 12hr
  • If unable to obtain CSF consider CTA
    • CTA also highly sensitive for predicting delayed cerebral ischemia

Workup

  • Brain CT without contrast
  • LP

Treatment

Physiologic derangements, such as hypoxemia, metabolic acidosis, hyperglycemia, BP instability, and fever, can worsen brain injury and has been independently associated with increased M&M, but no studies showing benefit of corrections.


AHA Aneurysmal SAH BP Guidelines[4]

  1. No well-controlled studies exist that answer whether BP control influences rebleeding
  2. BP should be controlled to balance the risk of stroke, hypertension-related rebleeding, and maintenance of cerebral perfusion pressure (Class I, Level of Evidence B).
  3. Nicardipine, labetalol, and esmolol are appropriate choices for BP control (Sodium nitroprusside may raise intracranial pressure and cause toxicity with prolonged infusion and should be avoided)


  • Avoid hypotension
    • Maintain MAP >80
    • Give IVF
    • Give pressors if IVF ineffective
  • Discontinue/reverse all anticoagulation
    • Coumadin - (Prothrombin complex conc or FFP) + vit K
    • Aspirin - DDAVP
    • Plavix - Platelets
  • Nimodipine
    • Prevents vasospasm (a/w improved neuro outcomes and decreased cerebral infarction)
    • Give 60mg q4hr PO or NGT only (never IV) within 96hr of symptom onset. NNT 13 to prevent one poor outcome
    • Keep an eye on BP for fluctuations
  • Magneisum
    • Controversial; prevents vasospasm acting as NMDA antagonist and a calcium channel blocker; maintain b/w 2-2.5 mmol/L
  • Seizure prophylaxis
    • Controversial; 3 day course may be preferable
    • Phenytoin, levetiracetam, carbamazepine and phenobarb. Phenytoin can be a/w worse neurologic & cognitive outcome
  • Glucocorticoid therapy
    • Controversial; evidence suggests is neither beneficial nor harmful
  • Glycemic control
    • Controversial; consider sliding scale if long pt stay in ED while awaiting ICU bed
  • Keep head of bed elevated
  • Aneurysm Tx
    • Surgical clipping and endovascular coiling are definitive tx
    • Antifibrinolytic - Controversial; if delayed aneurysmal tx, consider short term therapy (<72 hrs) with TXA or aminocaproic acid

Complications

  • Rebleeding
    • Risk is highest within first 24 hours (2.5-4%), particularly within first 6 hours
    • Usually diagnosed by CT after acute deterioration in neuro status
    • Only aneurysm treatment is effective in preventing rebleeding
  • Vasospasm
    • Leading cause of death and disability after rupture
    • Typically begins no earlier than day three after hemorrhage
    • Characterized by decline in neuro status
    • Aggressive treatment can only be started after aneurysm has been treated
      • Tx for symptomatic vasospasm: Triple-H therapy (hemodilution + induced hypertension (pressors) + hypervolemia), ballon angioplasty, or intra-arterial vasodilators.
        • Studies have not provided strong evidence of benefit Triple-H therapy
  • Cardiac abnormalities (?2/2 release of catecholamines due to hypoperfusion of hypothalamus)
    • Ischemia
      • Elevated troponin (20-40% of cases)
      • ST segment depression
    • Rhythm disturbances
      • Torsades, A-fib/flutter
    • QT prolongation
    • Deep, symmetric TWI
    • Prominent U waves
  • Hydrocephalus
    • Consider ventricular drain placement for deteriorating LOC + no improvement w/in 24hr
  • Hyponatremia
    • Usually due to SIADH
      • Treat via isotonic, or if necessary, hypertonic saline (do not treat via H2O restriction)
    • Rarely due to cerebral salt-wasting
      • Volume depleted, so treat with isotonic saline

Prognosis

Hunt and Hess

Subjective terminology, but good interobserver variability

  • Grade 0: Unruptured aneurysm
  • Grade 1: Asymptomatic or mild HA and slight nuchal rigidity
Grade 1a: No acute meningeal/brain reaction, with fixed neurological def
  • Grade 2: Moderate to severe HA, stiff neck, no neurologic deficit except CN palsy
  • Grade 3: Mild mental status change (drowsy or confused), mild focal neurologic deficit
  • Grade 4: Stupor or moderate to severe hemiparesis
  • Grade 5: Coma or decerebrate rigidity

Survival Rate

  • Grade 1: 70%
  • Grade 2: 60%
  • Grade 3: 50%
  • Grade 4: 20%
  • Grade 5: 10%


Grade 1 or 2 have curable disease
Add one grade for serious systemic disease (HTN, DM, severe atherosclerosis, COPD)

World Federation of Neurosurgical Societies (WFNS)

Objective terminology, and fair interobserver variability

  • Grade 1: GCS of 15, no motor deficits
  • Grade 2: GCS of 13 or 14, no motor deficits
  • Grade 3: GCS of 13 or 14, with motor deficits
  • Grade 4: GCS of 7–12, with or without motor deficits
  • Grade 5: GCS of 3–6, with or without motor deficits

Other scales are also available, including the Ogilvy and Carter scale (comprehensive, yet complex), and the Fisher scale or Claassen grading system (vasospasm index risk).

Note: First-degree relatives are at 2-5 fold increase in SAH, so screening is considered on individual basis.

See Also

Source

  1. Ottawa SAH Rule JAMA. 2013 Sep 25;310(12):1248-55. doi: 10.1001/jama.2013.278018
  2. Perry JJ, et al. Sensitivity of computed tomography performed within six hours of onset of headache for diagnosis of subarachnoid haemorrhage: prospective cohort study. BMJ. 2011; 343:d4277.

  3. van Gijn J and van Dongen KJ. The time course of aneurysmal haemorrhage on computed tomograms. Neuroradiology. 1982; 23:153–156.
  4. Bederson J. et al. Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage: A Statement for Healthcare Professionals From a Special Writing Group of the Stroke Council, American Heart Association. Stroke. 2009;40:994-1025 PDF